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Abstract
Autoimmune autonomic ganglionopathy (AAG) is a rare acquired channelopathy that is
characterized by pandysautonomia, in which autoantibodies to ganglionic nicotinic acetyl-
choline receptors (gAChR) may play a central role. Radioimmunoprecipitation (RIP) assays
have been used for the sensitive detection of autoantibodies to gAChR in the serum of pa-
tients with AAG. Here, we developed luciferase immunoprecipitation systems (LIPS) to di-
agnose AAG based on IgGs to both the α3 and β4 gAChR subunits in patient serum. We
reviewed the serological and clinical data of 50 Japanese patients who were diagnosed
with AAG. With the LIPS testing, we detected anti-α3 and -β4 gAChR antibodies in 48%
(24/50) of the patients. A gradual mode of onset was more common in the seropositive
group than in the seronegative group. Patients with AAG frequently have orthostatic hypo-
tension and upper and lower gastrointestinal tract symptoms, with or without anti-gAChR.
The occurrence of autonomic symptoms was not significantly different between the sero-
positive and seronegative group, with the exception of achalasia in three patients from the
seropositive group. In addition, we found a significant overrepresentation of autoimmune
diseases in the seropositive group and endocrinological abnormalities as an occasional
complication of AAG. Our results demonstrated that the LIPS assay was a useful novel tool
for detecting autoantibodies against gAChR in patients with AAG.
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Introduction
The ganglionic nicotinic acetylcholine receptor (gAChR) mediates fast synaptic transmission
in all peripheral autonomic ganglia (sympathetic, parasympathetic, and enteric ganglia) in the
peripheral autonomic nervous system. AChRs on autonomic neurons are typically composed
of two α3 subunits in combination with three other AChR subunits [1]. Although neurons of
the autonomic ganglia can express numerous neuronal AChR subunits, including α3, α4, α5,
α7, β2, and β4, the properties of the AChR at mammalian ganglionic synapses are most similar
to AChRs that are formed by α3 and β4 subunits [2].
Autoimmune autonomic ganglionopathy (AAG) is an acquired immune-mediated disorder
that leads to autonomic failure. The disorder is associated, at least in part, with autoantibodies
to the gAChR. Antibodies to the gAChR that are found in the serum of 50% of patients with
the acute or subacute form of AAG correlate with disease severity, and have been shown to be
pathogenic [3,4]. Several studies have reported that these autoantibodies induce the internali-
zation of cell-surface nicotinic gAChRs and thereby impair synaptic transmission [4,5]. Fur-
thermore, it has been demonstrated that antibodies to the α3 subunit of the gAChR or AAG
serum have been shown to directly cause autonomic dysfunction in experimental animal mod-
els of AAG [6,7]. Although these antibodies are proving to be useful serological markers of
AAG, the positivity of gAChR antibodies in acute or subacute panautonomic failure remains
around 50%. Cases of idiopathic pure autonomic neuropathy have been reported since 1975 in
Japan, and 29 cases of AAG have been reported [8]. However, no assays are available that de-
tect the antibodies to gAChR in Japan, and this has caused difficulty in the diagnosis of AAG.
Furthermore, antibodies to non-α3 subunits, including the β4 gAChR subunit, have not been
identified in AAG to date.
In this study, we attempted to develop a novel technique to detect the subunit-specific anti-
bodies of gAChR without the use of a radioisotope. Here we established luciferase immunopre-
cipitation systems (LIPS) using GL8990 that can detect antibodies that bind to the α3 or β4
gAChR subunits with high sensitivity. The radioimmunoprecipitation (RIP) assay using [125I]
labeled epibatidine has been used as a convenient method to detect autoantibodies to the
gAChR [9]. In the RIP, a subunit-specific antibody cannot be detected because of the epibati-
dine binding the pentamer form of the gAChR. In contrast, LIPS, which is a powerful diagnos-
tic technique for the serological testing of antibodies that are associated with many different
human pathogens, is suitable for detecting a subunit-specific antibody [10–13]. In order to pro-
vide higher performance on the LIPS, we selected a Gaussia luciferase (GL) mutant, called
GL8990, in this study. GL is the smallest marine luciferase that has been discovered [14]. GL
generates a greater signal intensity from cells in culture (1000-fold) compared with the Renilla
luciferase (RL) [15]. GL8990 (meaning F89W and I90L) is a GL mutant that is generated by site-
directed mutagenesis and that emits bioluminescence that is 10 times stronger and/or pro-
longed than intact GL [16]. Here we performed the LIPS that with the α3 or β4 gAChR subunit
fused to a luciferase to detect the respective autoantibodies in human sera. In addition, we ex-
tensively reviewed the histories and ongoing clinical and laboratory evaluations of 50 Japanese
patients who had been diagnosed with AAG and measured their antibodies to gAChR with the
LIPS. This study demonstrated the clinical features of AAG in patients in Japan and provides a
tool for precise disease diagnosis.
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Materials and Methods
Patients and serum samples
The series of subjects in this study was comprised of the groups of patients with AAG, healthy
controls (HC), and controls with other diseases (DC). Serum samples from 50 patients with
AAG were obtained from general and teaching hospitals throughout Japan between January
2012 and February 2014 (mean age, 52.5 ± 19.0 years old, 26 males and 24 females, Table 1).
The clinical diagnoses were made in each hospital and the patients' clinical data were provided
at the same time. Serum samples from patients showing limb muscle weakness or severe senso-
ry disturbance were excluded from the study. The control groups consisted of 73 HC (mean
age, 38.3 ± 11.1 years old, 31 males and 42 females) and 34 subjects with other diseases (DC:
for details see S1 Table. Detailed clinical characteristics of OND patients; mean age, 56.3 ± 20.4
years old, 19 males and 15 females).
Table 1. Clinical features of patients with AAG/APD.
Patients with AAG/APD Patients with AAG/APD, Anti-
gAChR Ab positive




Number of patients 50 24 26
Age (yr) 52.5 ± 19.0 51.9 ± 20.4 53.0 ± 18.1 0.838
Age at onset (yr) 48.8 ± 20.1 46.8 ± 20.8 50.7 ± 19.7 0.495
Sex (female, %) 24 (48.0) 13 (54.2) 11 (42.3) 0.413
Duration of the autonomic symptoms
(yr)
3.7 ± 6.9 5.1 ± 8.8 2.3 ± 4.1 0.344
Onset (%) Subacute: 25 (50.0),
Gradual: 25 (50.0)
Subacute: 9 (37.5), Gradual: 15
(62.5)
Subacute: 16 (61.5), Gradual: 10
(38.5)
0.095
Antecedent event (%) 11 (22.0) 4 (16.7) 7 (26.9) 0.212
Orthostatic hypotension and/or
orthostatic intolerance (%)
42 (84.0) 20 (83.3) 22 (84.6) 0.915
Sicca complex (%) 28 (56.0) 14 (58.3) 14 (53.8) 0.760
Coughing episodes (%) 8 (16.0) 4 (16.7) 4 (15.4) 0.915
Heat intolerance and/or anhidrosis (%) 34 (68.0) 15 (62.5) 19 (73.1) 0.435
Pupil abnormality (%) 20 (40.0) 11 (45.8) 9 (34.6) 0.281
Gastrointestinal tract symptoms (%) 46 (92.0) 22 (91.7) 24 (92.3) 0.951
Bladder dysfunction (%) 29 (58.0) 16 (66.7) 13 (50.0) 0.242
Sexual dysfunction a (%) 15 (57.7) 7 (63.6) 8 (53.3) 0.628
Other clinical features b (%) 15 (30.0) 8 (33.3) 7 (27.0) 0.633
Complication: endocrine disorder c (%) 5 (10.0) 3 (12.5) 2 (7.7) 0.588
Complication: autoimmune disease d
(%)
11 (22.0) 9 (37.5) 2 (8.0) 0.012
Complication: tumor e (%) 5 (10.0) 4 (16.7) 1 (3.8) 0.140
a. We reviewed the 26 male patients only.
b. Numbness, mental symptom, dementia, character change, and back pain
c. Amenorrhea, eating disorder, SIADH (Syndrome of inappropriate secretion of antidiuretic hormone), and panhypopituitarism
d. Still disease, PBC (primary biliary cirrhosis), Hashimoto disease, PMR (polymyalgia rheumatica), SLE (systemic lupus erythematosus), SS (Sjögren's
syndrome), Graves’ disease, RA (rheumatoid arthritis), fibromyalgia, and other autoantibodies positive
e. Ovarian tumor, pancreas cancer, mediastinal tumor, and paranasal cancer
doi:10.1371/journal.pone.0118312.t001
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Ethics
All of subjects gave their written, informed consent to participate in the present study. The
study was approved by the Ethics Committee of Nagasaki Kawatana Medical Center (Nagasaki,
Japan).
LIPS assay for the detection of autoantibodies to gAChR
To generate luciferase reporters for the gAChR α3 and β4 subunits (termed gAChRα3-GL and
gAChRβ4-GL, respectively) of the human gAChR, full-length human AChR α3 (P32297, Pro-
mega Corporation, Madison, WI, USA) or β4 (P30296, Promega Corporation) was fused to a
Gaussia luciferase (GL) mutant (GL8990) (Fig. 1). Human embryonic kidney (HEK) 293F cells
(Life Technologies Corportion, Graind Island, NY, USA) were transfected with the expression
plasmid encoding the gAChRα3-GL or the gAChRβ4-GL with FuGENE6 (Promega Corpora-
tion). Two days later, the transfected cells were solubilized with a Tris-based saline containing
1% TritonTM X-100. To detect the α3 or β4 gAChR antibodies, 100 μL of the soluble fraction,
containing gAChR α3-GL or gAChR β4-GL, was incubated with 15 μL of human serum for 1
hour at 4°C. Subsequently, the fraction was mixed with 15 μL of protein G-sepharose (GE
Healthcare, Little Chalfont, Buckinghamshire, UK) and 600 μL phosphate-buffered saline
(PBS) with 3% bovine serum albumin and 0.05% Tween 20 and incubated for several hours at
4°C. Following centrifugation and washes with PBS containing 0.05% Tween 20 twice, the bio-
luminescence activities of the luciferase reporters in the protein G-sepharose were measured
with a BioLux GL assay kit (New England Biolabs, Ipswich, MA, USA) and a Lumat LB 9507
luminometer (BERTHOLD TECHNOLOGIES GmbH & Co. KG, Bad Wildbad, Germany)
(Fig. 2). The luminometer output was measured in relative luminescence units (RLU). In order
to confirm the accuracy of the LIPS assay for the gAChR antibodies, we used commercially
available antibodies to human gAChR α3 and β4 (H-100 and S-15; Santa Cruz Biotechnology,
Inc., Dallas, TX, USA) as positive controls.
Fig 1. Schematic representation of the acetylcholine receptor (AChR) α3-Gaussia luciferase (GL) 8990. For the ganglionic AChR (gAChR)-LIPS assay,
human embryonic kidney (HEK) 293 cells were transfected with an expression plasmid for the gAChRα3 or β4-GL reporter.
doi:10.1371/journal.pone.0118312.g001
Ganglionic AChR Antibodies in AAG
PLOSONE | DOI:10.1371/journal.pone.0118312 March 19, 2015 4 / 19
Based on the data for anti-gAChRα3 and β4 antibodies from the 73 HC, the cut-off values
were calculated as the mean plus 3 standard deviations from the mean (SD). In this study, the
antibody levels were expressed as an antibody index (A.I.) that was calculated as follows:
A.I. = [measurement value of the sample serum (RLU)]/[the cut-off value (RLU)].The nor-
mal value that was established in this study from healthy individuals was<1.0 A.I.
The RIP assay for the detection of autoantibodies to gAChR
Sera from eight of the 50 patients with AAG had been examined previously for antibodies to
the gAChR with conventional RIP in the laboratory of Dr. Vernino. These assays for antibodies
against the AChR were performed as previously described. In brief, the antibodies were de-
tected with an immunoprecipitation assay in which the AChR antigen was solubilized from a
human neuroblastoma cell line (IMR-32) and complexed with iodine I125-labeled epibatidine
[3,4,17].
Our assay for the anti-gAChR antibodies may have a different sensitivity and specificity
compared with the RIP assay; therefore, we were able to compare the results of the two differ-
ent assays on these eight samples.
Fig 2. The Luciferase Immunoprecipitation Systems (LIPS). The soluble fractionated component from the solubilized HEK 293F cells, including the
gAChRα3 or β4-GL, reacted with human serum, and the specific luciferase activities of the gAChRα3 or β4-GL were found with the luminometer. The in vitro
LIPS assay can quantitatively evaluate an interaction between an antigen and an antibody with high sensitivity and without a radioisotope.
doi:10.1371/journal.pone.0118312.g002
Ganglionic AChR Antibodies in AAG
PLOSONE | DOI:10.1371/journal.pone.0118312 March 19, 2015 5 / 19
Clinical assessment of autonomic function
Patients with generalized or restricted autonomic dysfunction were identified in each partici-
pating hospital in Japan. All of the patients with AAG had dysfunction in at least one autonom-
ic domain, and they underwent a baseline assessment, which included a determination of the
gAChR α3 and β4 antibody levels. Subacute onset was defined as the reaching of the peak of
autonomic failure within 3 months, and chronic was defined as reaching of the peak after 3
months. Comprehensive clinical, hematologic, biochemical, neurological, and serologic assess-
ments of all patients were performed at baseline. In addition, cerebrospinal fluid analysis was
also conducted.
We inquired about the presence or absence of each of the following functions that are con-
trolled by the autonomic system: syncope or orthostatic hypotension for orthostatic intoler-
ance; sicca complex, dryness of the skin, or hypohidrosis/anhidrosis for heat intolerance;
pupillary dysfunction; diarrhea or constipation for dysfunction of the gastrointestinal system;
dysuria or urinary retention needing catheterization for bladder dysfunction; and sexual dys-
function. However, we were not able to assess the extent of each autonomic symptom rigorous-
ly with the composite autonomic scoring scale. Patients with known causes of autonomic
failure, including multiple system atrophy, diabetes, and amyloidosis were excluded.
Each patient went through autonomic testing, which involved the Schellong test, head-up
tilt test, measurement of the coefficient of variation in R-R intervals (CVR-R), noradrenaline
(NA) infusion test, pupillary response to local instillation, assessment of the plasma levels of
catecholamines, sweat testing, quantitative sudomotor axon reflex test (QSART), [123I] meta-
iodobenzylguanidine (123I-MIBG) myocardial scintigraphy, and cystometry. The physiologic
analog of noradrenaline, 123I-MIBG, traces the uptake and transport in both noradrenaline
presynaptic sympathetic nerve terminals and in subsequent vesicular storage [18]. Postgangli-
onic presynaptic cardiac sympathetic nerve endings can be noninvasively assessed by MIBG
scintigraphy because a reduction in cardiac MIBG uptake (H/M ratio) indicates postganglionic
sympathetic dysfunction. Cardiac MIBG uptake is reduced in patients with Lewy body diseases
such as Parkinson’s disease, as well as dementia with Lewy bodies [19,20]. In the standard pro-
cedure, the H/M ratio is calculated on early and delayed anterior chest planar images by draw-
ing a region of interest including the heart (H) and the other one over the upper mediastinum
(M). However, we were unable to unify the itemss of autonomic testing facilities among the
different hospitals.
Statistical analysis
Commercially available statistics software was used for the data analysis (SigmaPlot, Systat
Software, Inc., San Jose, CA, USA). The A.I. data that were normally distributed were analyzed
with one-way analysis of variance. For the data that were not normally distributed, a one-way
analysis of variance of ranks was employed. The significance level was set at P<0.05.
Results
Establishment of the LIPS assay for the detection of antibodies to the
gAChR
The RIP is a very useful tool for obtaining information about the total amount of antibodies to
gAChR, but it cannot distinguish subunit-specific antibodies [3]. In order to detect subunit-
specific antibodies for the gAChR, we prepared two subunit-specific luciferase reporters,
termed gAChRα3-GL and gAChRβ4-GL. In order to confirm that these subunit-specific lucif-
erase reporters work as a bait in the LIPS, we examined a LIPS assay that used ready-made
Ganglionic AChR Antibodies in AAG
PLOSONE | DOI:10.1371/journal.pone.0118312 March 19, 2015 6 / 19
gAChR subunit-specific antibodies. As shown In Fig. 3, there is a dose-dependent response was
observed between the amount of ready-made gAChR subunit-specific antibody and the
gAChR subunit-specific luciferase reporter activity. These data demonstrate that each gAChR
subunit-specific antibody properly bounds gAChRα3-GL or gAChRβ4-GL.
Detection of the autoantibodies to the gAChR in patients with AAG
Both the anti-gAChRα3 and anti-gAChRβ4 antibodies were determined by the LIPS assay to
be present in 0.0% (0 of 73) of the HC. In contrast, 48% (24 of 50) of the sera from patients
with AAG were positive for autoantibodies (p< 0.001, Fig. 4A). The anti-gAChRα3 antibodies
were detected in 23 samples and the anti-gAChRβ4 antibodies were detected in seven samples
(14.0%), as shown in Fig. 4B (p< 0.001). Both of the antibodies were detected in six samples.
The mean anti-gAChRα3 antibody levels in the HC and the DC were 0.305 A.I. and 0.336 A.I.,
respectively. These levels were significantly lower than the mean level in the AAG samples with
a mean level of 1.210 A.I. (p< 0.001, Fig. 4A). Similarly, the mean anti-gAChRβ4 antibody
level in HC was 0.367 A.I. and DC was 0.302 A.I., respectively. Those were significantly lower
than the AAG samples with a mean level of 0.618 A.I. (p< 0.001, Fig. 4B). In the DC group, we
detected anti-gAChRα3 antibodies in the serum of the patient with the suspected case of
amyloid neuropathy.
Clinical profile of the anti-gAChR antibody-positive and -negative
patients with AAG
The clinical characteristics of the patients are presented in Table 1. The age at the onset and the
duration of the autonomic symptoms were 48.8 ± 20.1 (mean ± standard deviation) years and
3.7 ± 6.9 years, respectively. The patterns of mode were divided into subacute and gradual
groups, according to the duration to the peak of autonomic symptoms. Half of the patients
with AAG had subacute onsets and half had chronic progressive presentations. Gastrointestinal
tract symptoms were the most frequently observed (92.0%). Table 1 compares the clinical fea-
tures between patients who were positive and those who were negative for the anti-gAChR
Fig 3. Confirmation of the LIPS assay system for the gAChRα3 or β4 with ready-made antibodies. The anti-gAChRα3 antibody (H-100) and the anti
gAChRβ4 antibody (S-15) bound the gAChRα3-GL and the gAChRβ4 reporters, respectively in a dose-dependent manner (a and b). The X-axis indicates the
amount of ready-made gAChRα3 or β4 antibody used. The Y-axis indicates the gAChRα3 or β4-GL activity. The line with closed diamonds shows the results
that were obtained in this experiment.
doi:10.1371/journal.pone.0118312.g003
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antibodies. Gradual onset was more common in the anti-gAChR antibody-positive patients
than in the antibody-negative patients (62.5% vs. 38.5%). No significant differences in the clini-
cal findings were noted, except for a higher frequency of other autoimmune disease complica-
tions in the patients who were positive for the anti-gAChR antibody compared to the
antibody-negative patients (37.5% vs. 8.0%, p = 0.012).
Clinical characteristics and autonomic symptoms of the patients with
AAG who were anti-gAChR antibody-positive (Table 2)
Table 2 summarizes the clinical characteristics and autonomic symptoms of the patients with
AAG. An antecedent event was reported in four patients shortly before the initiation of auto-
nomic symptoms. In our study, major autonomic symptoms, including orthostatic, sicca, sudo-
motor, papillary, gastrointestinal, and urinary symptoms were analyzed. Orthostatic
hypotension for orthostatic intolerance and gastrointestinal tract symptoms were observed in
20 (83.3%) patients and 22 (91.7%) patients, respectively. Gastrointestinal tract symptoms
were composed of various digestive system problems, such as constipation (n = 14), early sati-
ety (n = 4), vomiting (n = 4), abdominal pain (n = 4), anorexia (n = 4), diarrhea (n = 4), ileus
(n = 3), alternate stool abnormality (n = 3), taste impairment (n = 1), and achalasia (n = 3). Pu-
pillary dysfunction was observed in 11 patients, including two patients who had Adie’s tonic
pupil. The initial symptoms of seropositive AAG/acute pandysautonomia (APD) in 15 patients
(62.5%) were orthostatic hypotension, involving lightheadedness, orthostatic intolerance, or
syncope. The autonomic manifestations of the anti-gAChR antibody-positive patients were
widespread, and they affected both sympathetic and parasympathetic functions. However, 3
patients (Patient 6, 16, and 17) had only one symptom (disturbance of the digestive system,
bladder dysfunction, and orthostatic hypotension, respectively). Patient 6 had a history of re-
current ileus and severe abdominal pain. She previously had an operation to remove a sigmoid
volvulus 1 year before the onset of repeated ileus and abdominal pain. As for the other symp-
toms, attacks of coughing were observed in four patients (16.7%), and six patients (Patients 1,
5, 11, 12, 14, and 15) had a subjective numbness or superficial sensory disturbance in the
Fig 4. LIPS for gAChR in the sera from patients with autoimmune autonomic ganglionopathy (AAG) and controls.We tested the sera from patients
with AAG, disease controls (DC), and healthy controls (HC). a) Anti-gAChRα3 antibodies were detected in 23 samples. The mean anti-gAChRα3 antibody
level in the HC was 0.305 antibody index (A.I.), which was significantly lower than in the AAG samples with a mean level of 1.210 A.I. (p< 0.001). b) Anti-
gAChRβ4 antibodies were also detected in seven samples, as shown in Fig. 4B (p = 0.005). The mean anti-gAChRβ4 antibody level in the HC was 0.367 A.I.,
which was significantly lower than the measn level of 0.618 A.I. in the AAG samples (p< 0.001).
doi:10.1371/journal.pone.0118312.g004
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Table 2. Clinical and autonomic characteristics at baseline of anti-gAChR Ab positive AAG patients.
Patient Age Sex Onset
age























1 75 M 59 16 Gradual − + + − + + + + + Numbness − −
2[53] 60 M 60 0 Subacute + + + − + + + + − − Still disease susp. −
3 39 F 39 0 Subacute − + + − − − + − − ANA positive −
4 26 F 21 5 Gradual − − + − + + + + − Amenorrhea Ovarian tumor
5 68 M 53 15 Gradual − + − − − − + + + Numbness − −
6 37 F 35 2 Gradual − − − − − − + − − − − −
7 45 M 45 0 Subacute + + + − + + + + + − − −
8 60 M 60 0 Subacute − + + − + + + + + Mental
symptom
− −
9 79 F 77 2 Gradual − + − − − + + + Dementia PBC, Hashimoto dis. −
10 78 M 78 0 Subacute − + − − + − + − − − − −
11 67 M 59 8 Gradual − + + − − − + − − Numbness − −
12 49 M 12 37 Gradual − + + + + + + + + Sensory
disturbance
− −
13 73 F 66 7 Gradual − + + − + − + + − − Mediastinal
tumor




15 56 M 55 1 Gradual − + − + + − + + Numbness PMR, panhypopituitarism −
16 54 F 35 19 Gradual − − − − − − − + − − −
17 84 F 84 0 Gradual − + − + − − + + − − Paranasal
cancer
18 37 F 37 0 Subacute − + + − + + + + − SLE, SS −
19 38 F 39 0 Subacute − + − − − − − − − Graves' dis. Ovarian tumor
20 68 F 66 2 Gradual − + + − + − + + − RA, SS −
21 46 F 39 7 Gradual + + − − + − + + − RA, fibromyalgia −
22 49 F 47 2 Gradual − − + − − − + − − PBC −
23 6 F 6 0 Subacute + + + − + + + + − − −
24 36 M 35 0.5 Gradual − + + − + + + + + − − −
Initial symptoms were expressed in bold.
AE = antecedent event; OH = orthostatic hypotension; OI = orthostatic intolerance; HI = heat intolerance; AH = anhidrosis; GI = gastrointestinal tract symptoms; α3 Ab = ganglionic
acetylcholine receptor α3 antibody; β4 Ab = ganglionic acetylcholine receptor β4 antibody; A.I. = Antibody Index; AE = antecedent event; OI = orthostatic intolerance;
OH = orthostatic hypotension; HI = heat intolerance; AH = anhidrosis; GI = gastrointestinal tract symptoms; Dept = department
a. Subacute = peak of autonomic failure within 3 months; gradual = gradual onset of chronic autoimmune autonomic ganglionopathy with the peak of autonomic failure after
3 months.
b. Patient 2 = fever up; 7 = epididymitis; 21 = influenza virus type A infection; 23 = fever up and cough.
c. Patient 4 and 7 = Adie’s tonic pupil. The other cases had the abnormality of papillary reflex to light bilaterally or unilaterally.
d. Patient 1 = constipation; 2 = constipation; 3 = early satiety and vomiting; 4 = constipation; 5 = constipation; 6 = constipation, ileus, and sigmoid volvulus suspected; 7 = early
satiety, vomiting, alternate stool abnormality, abdominal pain, and taste impairment; 8 = constipation; 9 = constipation; 10 = constipation; 11 = anorexia and diarrhea; 12 = diarrhea
and achalasia; 13 = constipation, early satiety, vomiting, and ileus; 14 = abdominal pain, anorexia, and diarrhea; 15 = diarrhea; 17 = constipation, anorexia, and achalasia;
18 = alternate stool abnormality, abdominal pain, and anorexia; 20 = constipation; 21 = constipation; 22 = early satiety, ileus, alternate stool abnormality, and abdominal pain;



























extremities or trunk. Psychiatric symptoms were observed in three patients (Patient 8, 9, and
14). Patient 8 demonstrated infantilization after the onset of autonomic symptoms and had fre-
quent syncope with emotional strain. Patient 9 showed memory disturbances and apathy in
daily living, such as domestic duties. Patient 14 also demonstrated character changes, such as
the tendency to act in a childish manner. Three patients with the following endocrine disor-
ders: amenorrhea (Patient 4), syndrome of inappropriate secretion of antidiuretic hormone
(SIADH) (Patient 14), and panhypopituitarism (Patient 15). Nine patients presented the other
following autoimmune diseases: rheumatoid arthritis (n = 2), primary biliary cirrhosis (n = 2),
secondary Sjögren's syndrome (n = 2), Still disease (n = 1), Hashimoto disease (n = 1), poly-
myalgia rheumatica (n = 1), systemic lupus erythematosus (n = 1), Graves’ disease (n = 1), and
fibromyalgia (n = 1).
Autonomic function studies of the anti-gAChR antibody-positive patients
with AAG
Table 3 shows the results of the autonomic function studies of the anti-gAChR antibody-posi-
tive patients. Some information was missing because some of the hospitals did not have ade-
quate equipment for the autonomic function tests. Of these 24 patients, abnormalities the
orthostatic changes in systolic blood pressure and the CVR-R were observed at high rates
(86.4% and 75.0%, respectively). Cardiac MIBG uptake (H/M ratio), which was measured by
123I-MIBG myocardial scintigraphy in 11 anti-gAChR antibody-positive patients, was de-
creased in nine patients (81.8%). Urodynamic studies were performed in five of 24 patients. Re-
sidual urine of more than 50 mL was noted in four patients (80.0%). Sudomotor and cutaneous
vasomotor functions were assessed by thermoregulatory sweat testing in three patients and a
reduced ability to sweat was reported in two patients. Plasma norepinephrine values were mea-
sured in seven of 24 patients. Six had reduced supine norepinephrine below 100 pgmL-1
(85.7%). Pupillary responses to 1% phenylephrine, 5% tyramine, and 5% cocaine were exam-
ined in two patients (Patients 2 and 14) and 0.1 to 0.125% pilocarpine in two patients (Patients
4 and 7) in a totally dark room. In the former test, remarkable mydriasis was observed as a pu-
pillary response to the local instillation of 1% phenylephrine. In the latter test, the affected
Adie’s pupil reacted with miosis to low dose pilocarpine. We confirmed albuminocytologic dis-
sociation in seven of 12 patients (58.3%) in a cerebrospinal fluid analysis.
Illustrative cases
Patient 1: A 75-year-old man who had been affected by AAG for at least 15 years and who had
severe orthostatic hypotension (supine, 102/64 mmHg; sitting, 60/34 mmHg). He had recur-
rent syncope (8–10 times a day), dry mouth, heat intolerance, severe constipation, and great
difficulty in passing urine (he required intermittent self-catheterization). An examination con-
firmed anisocoria and numbness in the all of his extremities. The serum levels of the anti-
gAChR autoantibodies were 1.626 A.I. (α3) and 1.000 A.I. (β4). 123I-MIBG myocardial scintig-
raphy revealed a decreased H/M ratio (early, 1.554; delay, 1.320, Fig. 5A). The normal values
for the H/M range were from 1.9 to 2.8 with a mean of approximately 2.2. Based on the basis of
the diagnosis of AAG, he was treated with two doses of intravenous methylprednisolone
(IVMP), which was followed by intravenous immunoglobulin (IVIg), in order to reach a sus-
tained improvement of the autonomic symptoms. He maintained the improvements in the or-
thostatic hypotension and experienced complete recovery of gastrointestinal function with
IVMP and IVIg, which was followed by oral prednisolone. The levels of the anti-gAChR auto-
antibodies in Patient 1 converted to normal values after treatment (α3, 0.727 A.I.; β4, 0.473 A.
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Table 3. Autonomic function tests at baseline of anti-gAChR Ab positive AAG patients.

























1 75 M 1.626 1.000 0.060 + + + −
2 42) 60 M 2.163 0.389 1.220 + + + + +
3 39 F 1.000 0.638 − −
4 26 F 3.520 0.376 + + + + +
5 68 M 2.046 1.219 + − + + +
6 37 F 1.352 0.636
7 45 M 7.005 1.443 42.160 + + + + + −
8 60 M 1.008 0.494 + + + +
9 79 F 1.027 0.935 + + + −
10 78 M 1.419 0.737 + + + −
11 67 M 3.265 1.107 + + + +
12 49 M 0.937 1.428 +
13 73 F 1.103 0.877 + + + +
14 16 M 1.488 0.713 negative + + + + − + +
15 56 M 3.781 1.708 + + +
16 54 F 2.084 0.525
17 84 F 2.573 1.752 + + +
18 37 F 1.054 0.523 + − + + +
19 38 F 2.101 0.488 + + + −
20 68 F 1.542 0.952 + +
21 46 F 1.113 0.478 − − − −
22 49 F 3.154 0.336 0.100 − − −
23 6 F 1.275 0.456 + − +
24 36 M 1.936 0.323 + +
Anti-gAChRα3 Ab = ganglionic acetylcholine receptor α3 antibody; Anti-gAChRβ4 Ab = ganglionic acetylcholine receptor β4 antibody; A.I. = Antibody Index; OH = orthostatic
hypotension; HUTT = head-up tilt test; CV R-R = CV = coefficient of variation R-R interval; H/M ratio = heart-to-mediastinum ratio in 123I-MIBG myocardial scintigraphy;



























I.), and treatment resulted in a remarkably improvement of H/M ratio (early, 2.380; delay,
2.231, Fig. 5B).
Patient 4: A 25-year-old woman who had been affected by AAG for at least 5 years and who
had severe constipation. She developed orthostatic intolerance, dry mouth and eye (left), pho-
tophobia, and reduced sweating on the right side of the face. An examination revealed Adie’s
tonic pupil (left), loss of deep tendon reflexes in the four extremities, preserved sensations, and
normal muscle strength. We confirmed the orthostatic hypotension (supine, 108/58 mmHg;
standing, 75/32 mmHg). Autonomic function tests confirmed generalized autonomic failure.
She had developed several autonomic symptoms since the first episode of amenorrhea at the
age of 20. The level of the gAChRα3 antibody was 3.520 A.I. She was treated with plasma ex-
change (PE) and showed improvements in orthostatic intolerance, deep tendon reflexes, and
Adie’s tonic pupil in response to PE that was followed by oral prednisolone. Surprisingly, men-
struation started again after a series of immunotherapy. The level s of the anti-gAChRα3 anti-
body remained positive in this patient, but with a substantially reduced (1.151 A.I.).
Fig 5. [123I] meta-iodobenzylguanidine (MIBG) cardiac imaging. Early and Delayed. a)123I-MIBGmyocardial scintigraphy revealed that the
heart/mediastinum (H/M) ratio was decreased at the baseline (early, 1.55; delay, 1.32). A reduced HM ratio indicates peripheral noradrenergic depletion. b)
Combined immunomodulatory therapies resulted in a remarkable improvement in the H/M ratio (early, 2.38; delay, 2.23).
doi:10.1371/journal.pone.0118312.g005
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Comparison of the RIP and the LIPS assay for the detection of the
autoantibodies to the gAChR
Eight samples from patients who were previously measured for gAChR antibodies by the RIP
were also evaluated by the LIPS assay. Seventy-five percent (6/8) of the samples demonstrated
perfect agreement on both assays. Anti-gAChRα3 antibodies were detected in Patient 14 by the
LIPS assay, but this sample was seronegative in the RIP (Table 3). Another sample demonstrat-
ed an opposite pattern. We further evaluated the correlation between the level of the anti-
gAChRα3 antibody that was measured by LIPS and the level of the anti-gAChR antibody that
was measured by the RIP in four seropositive samples. Some of the samples tracked each other
well between the two assays.
Discussion
Since the gAChR was identified as an autoantigen that is associated with the pathogenesis of
AAG, it has been a challenge to search for gAChR-specific autoantibodies. RIA and cell-based
assays (CBA) have been available for the detection of autoantibodies to the gAChR in the sera
of patients with AAG [1,5]. In this study, we established the LIPS assay for the detection of
gAChR antibodies and examined AAG cases with subunit-specific antibodies for gAChR in
Japan for the first time.
For the the detection of subunit-specific antibodies to the ion-channels, Ching et al. have re-
ported that the use of the LIPS method to detects the subunit-specific autoantibody of the
AChR in patients with myasthenia gravis [21]. Myasthenia gravis (MG) is an autoimmune
channelopathy that is caused by autoantibodies to the apparatus of the neuromuscular junc-
tions (NMJs). In about 80% of the patient sera, autoantibodies to the muscle-type of the nico-
tinic AChR are detected [22]. It has been known that the AChR is a pentamer that is composed
of four subunits (α1, β1, γ or δ, and ε). Ching et al have demonstrated that in LIPS using the α1
AChR subunit that is fused to Renilla luciferase in LIPS was partly useful for the detection of
subunit-specific antibodies of the AChR. In the present study, gAChR autoantibodies were de-
tected by LIPS in about 48% of the patients with AAG, which indicated that our data on the fre-
quency of the gAChR autoantibodies matched the results of the previous study that used the
RIP. Furthermore, the levels of the gAChR antibody that were estimated by LIPS (the current
group) and the RIP (reported by studies from the Steven Vernino Laboratory and Mayo Medi-
cal Laboratories [Patient 1, 2, 7, 14, and 22, as shown in Table 3]) showed a similar tendency.
Together, these results demonstrated that the LIPS exhibits a similar performance to the RIP,
at least in the detection of autoantibodies to gAChR. Needless to say there is still a slight possi-
bility that a pentamer-specific antibody exists in the AAG patient serum, because these results
matched incompletely. In addition, we have identified a subunit-specific antibody for the
gAChR, the anti-AChRβ4 antibody for the first time. Another subunit specific antibody for
gAChR, anti-AChRα3 antibody, causes several autonomic dysfunctions in an experimental
AAGmodel [6,7,23]. However, it is unclear whether the anti-AChRβ4 antibody is involved in
the pathogenesis of AAG. Further studies are necessary to prove this, and we are planning to
test the autoantibodies for other subunits of the nicotinic AChR (e.g., α5, β2).
AAG has two patterns of onset. In the present study, a gradual mode of onset was more
common in the seropositive group than in the group that was seronegative for anti-gAChR an-
tibodies, although Sandroni et al. have reported that subacute onset was more common in the
seropositive group [24]. There was no difference between the demographic features of the sero-
positive patients in gradual onset and subacute AAG in seropositive patients (S2 Table. Demo-
graphic features of patients with subacute AAG/APD and gradual AAG/APD) and no
relationship between antibody status and the temporal profile. Subacute AAG was often
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preceded by an illness that was presumed to be a viral or bacterial infection. Patients with
chronic AAG with mild or restricted autonomic failure usually present with low antibody levels
whereas high levels of antibodies are associated with severe acute/subacute AAG subtypes.
However, the highest A.I., which was found in Patient 7, was associated with chronic AAG and
severe autonomic dysfunction. These findings suggested that it is necessary to compile infor-
mation about patients with AAG more precisely. The main findings of the clinical and auto-
nomic characteristics were that patients with AAG were associated with a high rate of
orthostatic hypotension for orthostatic intolerance and upper and lower gastrointestinal tract
symptoms in both the seropositive and seronegative group. There was no significant difference
in the occurrence of autonomic symptoms between the seropositive and seronegative group. It
remains possible that unknown autoantibodies and other causative agents exist in the seroneg-
ative group. Clinically, it is difficult to distinguish the chronic form of seronegative AAG from
other degenerative disorders of the autonomic nervous system (e.g., pure autonomic failure).
Of note, three patients had achalasia in the seropositive group. The pathogenesis of achalasia
remains unclear, but anti-gAChR antibodies might contribute to it. All of the anti-gAChR anti-
body-positive patients, except for Patients 6, 16, and 19, presented pandysautonomia. Patient 6
had been diagnosed with a chronic intestinal pseudo obstruction (CIPO) before being testing
with the autoantibodies. Our data were consistent with prior reports that showed that patients
with limited autonomic symptoms demonstrated a relatively lower A.I. Sandroni et al. have
previously reviewed other autonomic neuropathies that are associated with the gAChR anti-
body. Occasional positivity to gAChR antibodies has been found in postural orthostatic tachy-
cardia, CIPO, chronic idiopathic anhidrosis, and distal small fiber neuropathy [25]. All of these
were listed as possible clinical phenotypes of anti-gAChR autoimmunity, although they show
low antibody levels. The results of our study indicated a similar tendency and suggested a possi-
ble correlation between antibody levels and the phenotype of the dysautonomia. In the present
study, however, we were not able to perform a correlational analysis between the level of A.I.
levels and the clinical severity of the autonomic symptoms because we did not perform a quan-
titative assessment for autonomic dysfunction. Moreover, several research groups have re-
ported that patients with other neuroimmunological disorders (myasthenia gravis, Lambert-
Eaton myasthenic syndrome, Guillain-Barré syndrome, and chronic inflammatory demyelinat-
ing polyneuropathy) have autoantibodies to gAChR and autonomic symptoms [26–28]. We
need to verify the pathogenicity of these autoantibodies and the correlation between antibody
levels and disease severity.
The Patients with AAG in Japan were younger and more male predominant than those in
Western countries [8]. In the present study, Japanese patients with AAG also had a lower age
at onset. The seronegative and seropositive groups did not differ significantly in age and gen-
der, although the seropositive group showed a female predominance. Of the 29 Japanese pa-
tients previously reported, 10 (34.5%) had coughing episodes and 12 (41.4%) had psychiatric
symptoms. The present study found several anti-AChR antibody-positive patients with coughs
(Patients 12, 14, 15, and 17) and psychiatric symptoms (Patients 8, 9, and 14), but these pa-
tients had a low frequency when compared with the findings of previous reports. Baker et al. re-
ported encephalopathy co-occurring with classic subacute AAG [29]. They revealed the
presence of antibodies that were directed against both the central α4 and α7 nAChRs in the
serum of the patient. That study is the first case report of patients with AAG presenting with
antibodies directed against both peripheral and central nAChRs. Watson et al. found antibod-
ies that specifically blocked the function of α7 nAChRs in patients with Rasmussen encephalitis
[30]. Therefore, it may be necessary to establish a LIPS assay for the detection of autoantibodies
to these nAChRs. Six AAG anti-gAChR antibody-positive patients (Patients 1, 5, 11, 12, 14,
and 15) complained of subjective numbness as an extra autonomic symptom, and the
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numbness might have been caused by extensive disturbance of the sympathetic and parasym-
pathetic nervous system. However, this is an important symptom that may distinguish AAG
from other disorders such as acute autonomic sensory neuropathy, Guillain-Barré syndrome,
and chronic inflammatory demyelinating polyneuropathy. A nerve conduction study could be
performed to assess this, and a nerve biopsy may be necessary in the patient with AAG.
The seropositive group had a significant overrepresentation of autoimmune diseases. Auto-
nomic dysfunctions have been reported in association with Sjögren’s syndrome [31,32], sys-
temic sclerosis [33], systemic lupus erythematosus [34], rheumatoid arthritis [35,36], and
mixed connective-tissue disease [37]. Although AAG and the other autoimmune diseases can
coexist due to the same background of autoimmunity, few reports have referred to anti-gAChR
antibodies in these autoimmune diseases. In a previous report, the coexistence of AAG and Sjö-
gren's syndrome coexistence was found in two patients [38,39]. The frequency of positive anti-
gAChR antibody status in large populations or among patients with autonomic neuropathy in
Sjögren’s syndrome has not been determined. We believe it is important to clarify the clinical
and immunological characteristics of the coexistence of AAG and the other autoimmune dis-
eases. Additionally, attention should be paid to the endocrine disorders that are complications
of AAG, because there were five patients (Patients 4, 9, 14, 15, and 19) with endocrine disorders
in the study. Three of the five patients who were seropositive for the anti-gAChR antibodies
presented with amenorrhea, SIADH, and panhypopituitarism. Several Japanese neurologists
have already reported cases of acute pandysautonomia or acute autonomic and sensory neu-
ropathy (AASN) with amenorrhea and/or SIADH [40–42]. They have suggested that patients
with autonomic neuropathy might have both peripheral and central nervous system manifesta-
tions. The roles of nAChRs are associated with cholinergic neurotransmission, the modulation
of dopamine function, the influence of inflammation, and the activity of the hypothalamic-pi-
tuitary-adrenal axis [43,44]. We presumed that nAChRs are involved in a variety of neurologi-
cal systems that are implicated in the pathophysiology of central nervous system involvement
including endocrine disorders and psychiatric symptoms.
Ganglionic AChR antibodies have the potential to impair autonomic ganglionic synaptic
transmission [9,45,46]. Because both sympathetic and parasympathetic ganglia utilize nicotinic
cholinergic synapses, antibodies that interfere with ganglionic transmission could cause pandy-
sautonomia. Our clinical and serological observations suggest that pandysautonomia may be
mediated by autoantibodies that interfere with autonomic ganglionic transmission. The pa-
tients who were identified in the present study had a failure of both the sympathetic (orthostat-
ic hypotension and anhidrosis) and parasympathetic functions (gut dysmotility, sicca complex,
and pupil abnormalities). The autonomic function tests that were performed in this study were
incomplete and inadequate, but most of the results (H/M ratio in 123I-MIBG myocardial scin-
tigraphy and pupillary response to local instillation) demonstrated postganglionic parasympa-
thetic involvement. Kimpinski et al. characterized the unique sudomotor dysfunction in AAG
as widespread, predominantly postganglionic, and a result of lesions at both the ganglia and
distal axon [47]. Manganelli et al. have also demonstrated in a sudomotor function study and
skin biopsy findings, that there is postganglionic autonomic damage in patients with AAG
[48]. They attributed this damage to prolonged and severe impaired synaptic transmission.
These reports coincide with our deduction that the anatomic pattern of autonomic dysfunction
was predominantly postganglionic.
Another important observation was that the impairment of the autonomic function may be
partially reversible in AAG. Patients 1 and 4 (the illustrative cases) improved in response to im-
munotherapy (plasmapheresis, IVMP, IVIg, and immunosuppressant drugs) with symptomat-
ic therapy. We interpreted this improvement to be related to the correlation with a decrease in
the levels of anti-gAChR antibodies in each case. Some patients with seropositive AAG
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responded to treatment with IVMP, plasmapheresis, or IVIg, and most of these required com-
bined or subsequent treatments to maintain the improvement [49–53]. The more severely af-
fected patients who did not respond to IVMP or PP monotherapy benefited from combined
therapy with other first line therapy and immunosuppressant agents, such as prednisolone,
azathioprine, and rituximab [54]. They also required prolonged immunotherapy for sustained
clinical improvement. These results suggest that antibody production may be ongoing, and not
self-limited. Combined treatment with any of the immunosuppressant agents reduced antibody
production to levels that were adequate for clinical benefit in our patients. In Patient 4, men-
struation restarted after a series of immunotherapy, suggesting an autoimmune mechanism in
this process. Thus, immunotherapy can also be efficacious for treatment of the endocrinologi-
cal abnormalities of patients with AAG.
Some limitations existed in this study. The important limitations of this study were the ret-
rospective design and the small number of subjects. A prospective, multi-center, and clinical
observation is necessary to confirm the relationships between the antibody levels, symptoms,
and results of the autonomic functions tests. Additional experiments and investigations are
necessary to clarify the role of AChR β4 antibodies in the pathogenesis of AAG. In addition, we
need to compare the sensitivity and specificity of LIPS with the RIP for the measurement of au-
toantibodies to gAChR in spiraling numbers.
Our results demonstrated the usefulness of the LIPS assay as a new tool for detecting auto-
antibodies against gAChR in the patients with AAG. Furthermore, follow-up studies with a
greater number of patients with AAG are required to investigate the relationship between the
levels of gAChR autoantibodies and clinical features.
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